|Mr. Michael H. Tardugno||Exec. Chairman, Pres & CEO||539.25k||N/A||1951|
|Mr. Jeffrey W. Church||CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec.||354.04k||N/A||1957|
|Dr. Khursheed Anwer||Exec. VP & Chief Scientific Officer||315.32k||N/A||1960|
|Dr. Nicholas Borys||Sr. VP & Chief Medical Officer||381.83k||N/A||1959|
|Mr. Timothy J. Tumminello CPA||Chief Accounting Officer and Controller||N/A||N/A||1958|
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Celsion Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.